Multiple Sclerosis Clinical Trials in Boston, Massachusetts

23 recruitingBoston, Massachusetts

Showing 120 of 23 trials

Recruiting
Phase 3

Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.

Relapsing Multiple Sclerosis
Novartis Pharmaceuticals360 enrolled99 locationsNCT06846281
Recruiting
Phase 1

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

Malignant Solid NeoplasmHematopoietic and Lymphoid Cell NeoplasmRheumatoid Arthritis+11 more
National Cancer Institute (NCI)300 enrolled52 locationsNCT03816345
Recruiting
Phase 4

Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis

Multiple Sclerosis
National Institute of Allergy and Infectious Diseases (NIAID)123 enrolled12 locationsNCT05285891
Recruiting
Phase 3

Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis

Multiple Sclerosis
Sanofi1,600 enrolled384 locationsNCT06141473
Recruiting
Phase 3

Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab

Relapsing Multiple Sclerosis
TG Therapeutics, Inc.800 enrolled46 locationsNCT05877963
Recruiting

A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)

Multiple SclerosisRelapsing Multiple Sclerosis
TG Therapeutics, Inc.500 enrolled85 locationsNCT06433752
Recruiting
Phase 3

Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis

Multiple Sclerosis
Sanofi900 enrolled338 locationsNCT06141486
Recruiting
Phase 1

A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)

Myasthenia GravisMultiple Sclerosis
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company120 enrolled35 locationsNCT06220201
Recruiting
Phase 1Phase 2

PET Brain Imaging in Multiple Sclerosis, Alzheimer's Disease, and Other Neurological and Neuropsychiatric Diseases

Multiple Sclerosis
Brigham and Women's Hospital250 enrolled1 locationNCT02649985
Recruiting
Early Phase 1

Assessment of Synaptic Density in MS

Multiple Sclerosis
Brigham and Women's Hospital30 enrolled1 locationNCT04634994
Recruiting
Phase 4

Glucose Consumption in MS Using [F-18]FDG-PET

Multiple Sclerosis
Brigham and Women's Hospital50 enrolled1 locationNCT07087106
Recruiting
Phase 2

A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years

Multiple Sclerosis
ModernaTX, Inc.180 enrolled17 locationsNCT06735248
Recruiting

A Novel Wearable Digital Biomarker for Detecting Changes in Multiple Sclerosis (MS) Condition

Multiple Sclerosis
Celestra Health Systems90 enrolled3 locationsNCT05781113
Recruiting

Care in Multiple Sclerosis (MS)

Multiple Sclerosis
NYU Langone Health386 enrolled6 locationsNCT07011914
Recruiting
Phase 2

A Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Patients

Secondary Progressive Multiple Sclerosis
Tiziana Life Sciences LTD54 enrolled7 locationsNCT06292923
Recruiting
Not Applicable

Vascular Mechanisms, Functional Outcomes, & Exercise Among Persons With Multiple Sclerosis With Hypertension

HypertensionMultiple Sclerosis
University of Massachusetts, Boston80 enrolled1 locationNCT06554340
Recruiting
Phase 2

Nasal Foralumab in Patients With Non-Active Secondary Progressive Multiple Sclerosis

Non-Active Secondary Progressive Multiple Sclerosis
Tiziana Life Sciences LTD55 enrolled1 locationNCT06890923
Recruiting

Prevalence and Impact of Obstructive Sleep Apnea in Multiple Sclerosis

Multiple SclerosisObstructive Sleep Apnea
Beth Israel Deaconess Medical Center800 enrolled1 locationNCT04603196
Recruiting

Genes and Environment in Multiple Sclerosis

Multiple Sclerosis
Columbia University5,000 enrolled5 locationsNCT01353547
Recruiting
Phase 1

Investigating the Utility of Demyelination Tracer [18F]3F4AP in Controls and Multiple Sclerosis Subjects

Multiple Sclerosis
Massachusetts General Hospital60 enrolled1 locationNCT04699747